W. Watson

Advances in the management of high‐risk localised and metastatic prostate cancer

D. Kuban, H. Huland, L. Klotz, 2012, BJU international.

Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer.

J. Logan, B. Delahunt, H. Samaratunga, 2022, Pathology.

Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes

L. O’Driscoll, S. Rani, K. O’Brien, 2012, PloS one.

Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer

D. Brennan, W. Gallagher, R. McDermott, 2021, Clinical Epigenetics.

Future of biomarker evaluation in the realm of artificial intelligence algorithms: application in improved therapeutic stratification of patients with breast and prostate cancer

W. Gallagher, Arman Rahman, C. Mooney, 2021, Journal of Clinical Pathology.

The use of LC‐MS to identify differentially expressed proteins in docetaxel‐resistant prostate cancer cell lines

L. O’Driscoll, M. Henry, P. Meleady, 2012, Proteomics.

Commercialized biomarkers: new horizons in prostate cancer diagnostics

W. Gallagher, R. Watson, M. Prencipe, 2015, Expert review of molecular diagnostics.

Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation

C. Dowling, R. Watson, W. Watson, 2009, Molecular Cancer.